Department of Psychology and Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada.
Department of Psychology and Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Addict Behav. 2023 Feb;137:107508. doi: 10.1016/j.addbeh.2022.107508. Epub 2022 Sep 29.
Cannabis is associated with a range of therapeutic and non-therapeutic, positive and negative effects. While some benefits and harms may be specific to individual cannabinoid constituents (THC, CBD), individual expectancies may also play a role.
Evaluate the extent to which individuals hold expectancies about the effects of CBD, THC, and THC & CBD combined, and whether this differs with prior cannabis experience.
Canadian adults (N = 345; n = 58 no prior cannabis use, n = 287 prior cannabis use) completed a Qualtrics survey. Participants provided information regarding their expectancies about the effects of cannabinoids (THC, CBD, THC & CBD combined) via a 15-item questionnaire, which included various therapeutic (e.g., helps with pain) and non-therapeutic positive (e.g., enhances positive feelings) and negative (e.g., risk for addiction) effects. They recorded their perceptions about the effects of each cannabinoid on a scale (0="definitely not true", 10="definitely true"). Data was analyzed using linear mixed models.
For most therapeutic effects, CBD-containing products (CBD, THC & CBD) were rated higher than THC. For most positive and negative non-therapeutic effects, THC-containing products (THC, THC & CBD) were rated higher than CBD. Those with prior cannabis use (vs no prior use) rated all cannabinoids higher regarding their association with many therapeutic and positive effects, while endorsing weaker expectancies about their role in some negative effects.
Adults endorsed stronger expectancies that CBD-containing products are responsible for producing a rage of therapeutic effects. Those with prior cannabis use experience tended to emphasize the benefits and minimize potential harmful effects of cannabinoids.
大麻与一系列治疗和非治疗、积极和消极的影响有关。虽然一些益处和危害可能特定于单个大麻素成分(THC、CBD),但个体期望也可能发挥作用。
评估个体对 CBD、THC 和 THC+CBD 联合作用的影响的期望程度,以及这种期望是否因先前的大麻使用经验而有所不同。
加拿大成年人(N=345;n=58 无先前大麻使用,n=287 有先前大麻使用)完成了一份 Qualtrics 调查。参与者通过一份 15 项的问卷提供了关于他们对大麻素(THC、CBD、THC+CBD 联合)作用的期望的信息,其中包括各种治疗性(例如,缓解疼痛)和非治疗性积极(例如,增强积极情绪)和消极(例如,成瘾风险)的影响。他们在一个量表上记录了对每种大麻素作用的感知(0="绝对不真实",10="绝对真实")。使用线性混合模型分析数据。
对于大多数治疗性效果,含 CBD 的产品(CBD、THC+CBD)的评分高于 THC。对于大多数非治疗性积极和消极效果,含 THC 的产品(THC、THC+CBD)的评分高于 CBD。与无先前使用相比,有先前使用大麻经验的参与者(vs 无先前使用)对所有大麻素在与许多治疗性和积极效果相关的方面给予了更高的评价,同时对它们在一些消极效果方面的作用持较弱的期望。
成年人对 CBD 含量产品产生一系列治疗效果的期望更强。有先前大麻使用经验的参与者倾向于强调大麻素的益处,并最小化其潜在的有害影响。